DAPK2 and breast carcinoma: Recently, Su showed that miR-520h could enhance the chemoresistance of breast cancer cells to paclitaxel by targeting DAPK2 [24] and that miR-520h expression might be an indicator of poor prognosis in breast cancer patients.